News
MedPage Today on MSN17h
Novel Combination Shows Efficacy, Safety in Mid-Stage MASH Trial
Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback